Financial Content – Torigen Pharmaceuticals, a company developing personalized cancer immunotherapies for the veterinary market, announced today the completion of a $3.1 million Series A financing round led by Connecticut Innovations, which included the conversion of outstanding convertible debt and interest.
Torigen Pharmaceuticals Secures $3.1 Million in Series A Financing
February 18, 2019